EIKO Lifesciences Intrinsic Value
EIKO Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹37.44 | ₹29.95 - ₹44.93 | -26.7% | EPS: ₹3.12, Sector P/E: 12x |
| Book Value Method | asset | ₹40.71 | ₹36.64 - ₹44.78 | -20.3% | Book Value/Share: ₹40.71, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹27.43 | ₹24.69 - ₹30.17 | -46.3% | Revenue/Share: ₹34.29, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹33.11 | ₹29.80 - ₹36.42 | -35.2% | EBITDA: ₹8.00Cr, EV/EBITDA: 6x |
| PEG Ratio Method | growth | ₹19.97 | ₹17.97 - ₹21.97 | -60.9% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹25.71 | ₹23.14 - ₹28.28 | -49.7% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹28.57 | ₹25.71 - ₹31.43 | -44.1% | ROE: 7.0%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹53.46 | ₹48.11 - ₹58.81 | +4.6% | EPS: ₹3.12, BVPS: ₹40.71 |
Want to compare with current market value? Check EIKO share price latest .
Valuation Comparison Chart
EIKO Intrinsic Value Analysis
What is the intrinsic value of EIKO?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of EIKO Lifesciences (EIKO) is ₹33.11 (median value). With the current market price of ₹51.09, this represents a -35.2% variance from our estimated fair value.
The valuation range spans from ₹19.97 to ₹53.46, indicating ₹19.97 - ₹53.46.
Is EIKO undervalued or overvalued?
Based on our multi-method analysis, EIKO Lifesciences (EIKO) appears to be trading above calculated value by approximately 35.2%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 11.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.16 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 7.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 15.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.73x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for EIKO Lifesciences
Additional stock information and data for EIKO
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹3 Cr | ₹-3 Cr | Positive Operating Cash Flow | 6/10 |
| March 2020 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2019 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2018 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2017 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |